Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus.
Eli Lilly & Co., Vienna, Austria; J.J. Strossmayer Medical School, Osijek, Croatia.
Z
Z
Milicevic